Cartilage Restoration denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cartilage restoration are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Blue Cross Blue Shield Issues a Non-Formulary Denial for Cartilage Restoration

Although cartilage restoration is primarily a surgical procedure, certain components — including biologic scaffolds, cell-based implants, or related pharmaceutical products used during the procedure — may be subject to BCBS formulary management. A non-formulary denial in this context typically means that the specific product used (e.g., a particular off-the-shelf cartilage matrix, biologic graft material, or implantable device) is not on BCBS's approved-product list, or that the procedure was performed using a product that requires a separate formulary-exception or prior-authorization pathway that was not initiated.

## Why This Denial Is Appealable

Non-formulary denials for surgical biologics or implants are appealed successfully when there is no equivalent formulary alternative available for the specific clinical indication, or when the non-formulary product was chosen for documented patient-specific reasons. Unlike oral medications, surgical implants and biologics often lack true therapeutic substitutes — the "formulary alternative" BCBS might point to may not be appropriate for the same type of cartilage lesion or surgical approach.

## Federal Appeal Framework

• Internal appeal: File within the Explanation of Benefits deadline. Request from BCBS a list of any formulary alternatives it considers equivalent for this procedure.
• Formulary exception request: File alongside or instead of the standard appeal if BCBS has a distinct exception pathway for surgical products; many plans do.
• Expedited review: Available if delay poses a serious health risk.
• External Independent Review (ACA §2719): Available after internal exhaustion; binding on the plan.
• ERISA §503: Full-and-fair review for employer plans; external-review window is approximately four months from denial.

## Documentation to Gather

1. Product identification — the exact name, manufacturer, and FDA clearance or approval status of the specific product used or requested. 2. No-equivalent-alternative documentation — a letter from the treating surgeon explaining why no formulary-listed alternative is appropriate for this patient's specific lesion type, size, or surgical approach. 3. Clinical-selection rationale — operative planning notes or consultation records documenting why this specific product was chosen. 4. Prior conservative-treatment history — records confirming the patient reached the point where surgical intervention was warranted. 5. Applicable guideline reference — citation to the applicable professional society guideline supporting use of this product category for the relevant indication.

## Criteria-Mapping Structure

Obtain BCBS's formulary-exception or non-formulary-review policy for surgical biologics or implants. Left column of your appeal table: each exception criterion; right column: the specific document (surgeon's letter, FDA clearance, guideline citation, or operative note) that satisfies it. If BCBS identifies a formulary alternative, address each alternative individually in the table and document the clinical reason it is not appropriate for this patient. A clear, exhaustive table makes it difficult to sustain a non-formulary denial when no true equivalent exists.